ES2191096T3 - Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos. - Google Patents

Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos.

Info

Publication number
ES2191096T3
ES2191096T3 ES96912205T ES96912205T ES2191096T3 ES 2191096 T3 ES2191096 T3 ES 2191096T3 ES 96912205 T ES96912205 T ES 96912205T ES 96912205 T ES96912205 T ES 96912205T ES 2191096 T3 ES2191096 T3 ES 2191096T3
Authority
ES
Spain
Prior art keywords
antagonists
human
join
interleucine
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96912205T
Other languages
English (en)
Inventor
Gennaro Ciliberto
Rocco Savino
Giacomo Paonessa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2191096T3 publication Critical patent/ES2191096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANTAGONISTAS DE LA INTERLEUQUINA 6 HUMANA QUE SON TOTALMENTE INCAPACES DE UNIRSE A LA CADENA DEL RECEPTOR RESPONSABLE DE LA TRANSDUCCION DE LA SEÑAL ASOCIADA CON ESTA CITOQUINA, ESTO ES, CON GP130. LA FIGURA MUESTRA LA AUSENCIA DE INTERACCION ENTRE LOS ANTAGONISTAS DE LA INTERLEUQUINA 6 HUMANA DE ACUERDO CON LA INVENCION Y LA PROTEINA GP130.
ES96912205T 1995-04-28 1996-04-26 Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos. Expired - Lifetime ES2191096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000273A IT1276555B1 (it) 1995-04-28 1995-04-28 Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni

Publications (1)

Publication Number Publication Date
ES2191096T3 true ES2191096T3 (es) 2003-09-01

Family

ID=11403338

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96912205T Expired - Lifetime ES2191096T3 (es) 1995-04-28 1996-04-26 Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos.

Country Status (11)

Country Link
US (1) US5972902A (es)
EP (1) EP0822986B1 (es)
JP (2) JP3373856B2 (es)
AT (1) ATE233320T1 (es)
CA (1) CA2218372C (es)
DE (1) DE69626387T2 (es)
DK (1) DK0822986T3 (es)
ES (1) ES2191096T3 (es)
IT (1) IT1276555B1 (es)
PT (1) PT822986E (es)
WO (1) WO1996034104A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017441A1 (fr) * 1995-11-07 1997-05-15 Kaneka Corporation Autoantigenes
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
IT1291932B1 (it) * 1997-06-20 1999-01-21 Angeletti P Ist Richerche Bio Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma
ES2241583T3 (es) 2000-03-06 2005-11-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de antagonistas de interleuquina 6 para el tratamiento de tumores dependientes de estrogenos.
IL161968A0 (en) * 2001-11-14 2005-11-20 Centocor Inc Anti-il-6 antibodies, compositions, methods and uses
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
ITRM20050103A1 (it) * 2005-03-10 2006-09-11 Rocco Savino Associazione di antagonisti della interleuchina 6 e farmaci antiproliferativi.
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.

Also Published As

Publication number Publication date
PT822986E (pt) 2003-07-31
CA2218372A1 (en) 1996-10-31
IT1276555B1 (it) 1997-11-03
JPH10506538A (ja) 1998-06-30
DE69626387D1 (de) 2003-04-03
DE69626387T2 (de) 2003-12-11
EP0822986A1 (en) 1998-02-11
ITRM950273A1 (it) 1996-10-28
CA2218372C (en) 2001-07-31
JP2003153691A (ja) 2003-05-27
ATE233320T1 (de) 2003-03-15
DK0822986T3 (da) 2003-04-28
EP0822986B1 (en) 2003-02-26
US5972902A (en) 1999-10-26
JP3373856B2 (ja) 2003-02-04
ITRM950273A0 (it) 1995-04-28
WO1996034104A1 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
ES2191096T3 (es) Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos.
IT1288388B1 (it) Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
TR199700652T1 (xx) �nsan interl�kosit-1 resept�r yard�mc� proteini.
HK1008346A1 (en) Cytokine antagonists
ES2180798T3 (es) Derivados de pirimidina como antagonistas del receptor de 5ht2c.
WO2004059285A3 (en) Tumor killing/tumor regression using cxcr4 antagonists
HN1998000155A (es) Medicamentos
ES2164054T3 (es) Antagonistas de receptores de endotelina.
HUP0303952A2 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
PT911340E (pt) Isoquinolinas-3-carboxamidas substituidas, sua preparacao e utilizacao como farmacos
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
DE69837606D1 (de) Cystein-reiche rezeptoren-train
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
ES2097748T3 (es) Uso de derivados funcionales de la molecula de adhesion intercelular icam-1 en la terapia antivirica.
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
ES2171196T3 (es) Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño.
ES2169763T3 (es) Derivados de pirimidinona.
BR9815335A (pt) Uso de antagonistas de receptor de endotelina.
ES2107431T3 (es) Agentes con accion selectiva sobre los receptores de la adenosina.
PT906268E (pt) Fluorenonas com substituicao alquiloxiamino e sua utilizacao como inibidores da proteina quinase c
BR9812404A (pt) Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina
ATE57526T1 (de) P-acylaminobenzamide.